• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Ginkgo Bioworks Holdings Inc.

    4/29/25 4:02:34 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email
    DEFA14A 1 defa14a-notices.htm DEFA14A Document

     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    SCHEDULE 14A
    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    (AMENDMENT NO.    )
     
    Filed by the Registrant  ☒
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
    ☐    Preliminary Proxy Statement
    ☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐    Definitive Proxy Statement
    ☒    Definitive Additional Materials
    ☐    Soliciting Material under §240.14a-12
    GINKGO BIOWORKS HOLDINGS, INC.
    (NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
    (NAME OF PERSON(S) FILING PROXY STATEMENT, IF OTHER THAN THE REGISTRANT)
    Payment of Filing Fee (Check all boxes that apply):
    ☒    No fee required.
    ☐    Fee paid previously with preliminary materials.
    ☐    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
     
     





    noticepage_1.jpg



    noticepage_2.jpg



    noticepage_3.jpg



    noticepage_4.jpg

    Get the next $DNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Potter Myrtle S converted options into 10,822 shares (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      6/13/25 4:24:04 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Hannan Kathy Hopinkah converted options into 10,822 shares, increasing direct ownership by 259% to 15,003 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      6/13/25 4:19:19 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sloan Harry converted options into 10,822 shares, increasing direct ownership by 4% to 271,418 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      6/13/25 4:17:11 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/16/24 5:08:50 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/14/24 5:16:23 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care